Report topline data for the Phase 3 APOLLO study
Deadline not yet reached (65 days left)
- Announced
- 13 Feb 2026
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ongoing Phase 3 APOLLO study potential to serve as basis for traditional approval; topline data anticipated Q4 2026”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 13 Feb 2026
Deadline 31 Dec 2026 (“Q4 2026”) · wording expected
-
Version 2 · stated 30 Jul 2026
Deadline 31 Dec 2026 (“Q4 2026”) · wording firm
“On track to report APOLLO topline results in Q4 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- APOLLO study topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-IRON-002225 · Corrections policy